Soleno is developing a once-daily oral tablet, diazoxide choline, in Phase III clinical trials for the treatment of Prader-Willi Syndrome. No therapies are approved to treat this rare genetic condition, which causes chronic insatiable hunger as well as behavioural problems, cognitive disabilities, low muscle tone and short stature. The product has orphan drug designation in the US and Europe. Soleno is a VIPE (Venture Investment in Public Equity) and is listed on Nasdaq.

LocationRedwood City, California
CEOAnish Bhatnagar
Partner Andrew Sinclair
Websitewww.soleno.life